My question is whether this is a myth (and where does it come from?) or reality based in scientific facts...?
As a counterargument, I read the book "Anticancer" by David Servan-Schreiber, and although I don´t have the book with me now, so the quote is not exact, in one chapter Dr.Schreiber writes that sometimes after removing the tumor (not specifically prostate), the leftover cells can become more agressive - here he gives analogy of a mother spaceship that likes to control its smaller ships, once the mother ship is removed, the "kids" can go wild. Again, I do not remember whether he based this on any reliable science.
I do believe, there should be some studies done to examine this point, although creating such studies would pose some challenges, I imagine. This would help with the decision whether or not to operate in cases where the tumor burden in prostate is already high. What do you think?
Father (69 now) diagnosed with PCs in Jan 2011:
DRE positive, PSA 7.5, biopsy Gleason 6, second expert opinion: Gleason 7 and 8.
two inconclusive bone-scintigraphies, MR scan showed 2 bone mets
Feb 2011: Started hormonal therapy (Trelstar+Casodex) in Jan 2011
Jan 2012: Added Zometa
Mar 2012: went "off" hormonal therapy after PSA reached 0.055
Moderator - Prostate Cancer
(Not a medical professional)
DaVinci 10/2009
My adjuvant IGRT journey (2010) -
www.healingwell.com/community/default.aspx?f=35&m=1756808
HT (Lupron) 6-mo injection 9/12
But I do know if you go to YANA site and filter by status="deceased" and treatment type ="surgery"
http://www.yananow.org/query_stories.php#topoflist
It makes for interesting reading.
Tim Barber's story is never easy.
Brook
www.ncbi.nlm.nih.gov/pubmed/22313515
and this one: www.ncbi.nlm.nih.gov/pubmed/20942833
Both report favorably on debulking in specific limited conditions.
** I am not a doctor. My opinions are not medical advice. **
DX age 54 9/2012 PSA 5.3, DRE-, high PSAV. Clinical T1c
Biopsy: Gleason 3+4 with PNI / PC in 6 of 14 cores / 10% of length
Tx: RRP 2/2010
Pathology: pT2cNxMx / G 3+4 / PNI+ / SM- / SV- / EPE- / Volume 3cc /
PSA in 2010: <0.01 | 0.01 | 0.01 PSA in 2011: .01 | .02 | .02 | .01
PSA in 2012: .039 | .039 | .043
www.ncbi.nlm.nih.gov/pubmed/22313515
Here's the abstract:
Debulking surgery in the setting of very high-risk prostate cancer scenarios.
Oderda M, Joniau S, Spahn M, Gontero P.
Source
University of Turin, Department of Urology 1, A.O.U. San Giovanni Battista, Turin, Italy.
Abstract
What's known on the subject? and What does the study add? Nowadays radical prostatectomy (RP) is considered an effective treatment in high-risk prostate cancer (PCa) and the indications for a surgical approach are expanding, even in cases of very high PSA or node-positive disease. We explored the outcomes of debulking surgery in the setting of these very high-risk PCa patients, in order to assess its feasibility. This review confirms the important role achieved by surgery in the complex setting of patients with very high-risk PCA. Excellent survival rates have been reported, even when PSA exceeds 100 ng/mL. The completion of RP with lymphadenectomy might give a survival benefit in patients who were found intraoperatively to be node-positive. Furthermore, salvage RP confirmed to be the most effective treatment option after RT failure. On the contrary, up-to-date surgery of isolated nodal recurrences has shown only little benefit. Finally, there is no evidence supporting the efficacy of debulking surgery in metastatic or in hormone-refractory tumours. An accurate selection of the patient is essential.
OBJECTIVE:
To conduct a critical analysis of the available literature on the feasibility of debulking surgery in the setting of very high-risk prostate cancer (PCa) scenarios.
PATIENTS AND METHODS:
We performed a systematic literature search of PubMed and Embase using combinations of the following keywords: radical prostatectomy, surgery, high-risk, high PSA (prostate-specific antigen), radiorecurrent, hormone-refractory, metastatic prostate cancer, salvage. With the term 'very high-risk PCa' we indicated a clinical disease beyond the common definition of high-risk PCa, i.e. any clinical stage > T3, N0 or N+, any PSA level > 50 ng/mL and any recurrent disease after primary treatment.
RESULTS:
Radical prostatectomy (RP) achieved excellent survival rates in high-risk PCa, even in patients with very high PSA level. The completion of RP with lymphadenectomy might give a survival benefit in patients who were found intraoperatively to be node-positive. Salvage RP was confirmed to be the most effective treatment option after radiotherapy failure, with increased functional outcomes and decreased side-effects in the most recent series. Surgery of isolated nodal recurrences after previous radical therapy has shown little benefit according to the few available series. There is no evidence supporting the efficacy of debulking surgery in metastatic or hormone-refractory PCa.
CONCLUSION:
Debulking surgery achieved an important role in several aggressive PCa scenarios. An accurate selection of the patient is essential.
© 2012 BJU INTERNATIONAL.
60
Slow PSA rise 2007-2012: 1.4=>8
4 biopsies 2010-2012:
1)neg (inflammation observed),
2)neg,
3)positive one of 14 cores GS6(3+3) 3-4%, 2nd opinion GS7(3+4)
4)neg.
Moderate Pre-op ED
DaVinci RRP 6/14/12. left nerve spared
Post-op path: pT3a pN0 R1 GS9(4+5) Pos margins on rt
Start 24 mo ADT (Triple w/ Lupron) 7/26/12
Start adjuvant IMRT 10/17/12 done 12/13/12
Incontinent, Trimix, VED for Rehab
Age 52; dx at 50, PSA 54.9
open RP, 2010; removed 14 lymph nodes
Pathology report: T3bN0MX, SVI, neg margin, G9(5+4)
36 mo of ADT2: 24 down, 12 to go
Adjuvant RT, 75.6 Gy, including lymph nodes, 9/11
Adjuvant Taxotere (6 x 60 mg/m2), 6/12
Latest PSA <0.1, T=25
age: 57
12/09 -- PSA 6.8
G7 -- 3+4
HT, BT and IGRT
9/4/12 -- 2-year post treatment PSA 0.2
(PSAs .2, .3, .2, .3, .2)
Father (69 now) diagnosed with PCs in Jan 2011:
DRE positive, PSA 7.5, biopsy Gleason 6, second expert opinion: Gleason 7 and 8.
two inconclusive bone-scintigraphies, MR scan showed 2 bone mets
Feb 2011: Started hormonal therapy (Trelstar+Casodex) in Jan 2011
Jan 2012: Added Zometa
Mar 2012: went "off" hormonal therapy after PSA reached 0.055
Often, I read on this forum term "debulking" referring to surgery of the prostate, when surgery is done to remove the "bulk" of the tumor or reduce the tumor burden, even though there may an understanding before the surgery that there may be "cells" that would have probably already escaped the prostate.
My question is whether this is a myth (and where does it come from?) or reality based in scientific facts...?
I’m a little baffled at what question this is actually trying to ask. I have absolutely no clue what you are referring to as possible “myth.”
Is debulking a component of a credible treatment strategy? Is some cases, absolutely. Every case is different, and debulking is not common for most cancers.
Surgical debulking of tumors is a procedure whereby a portion of cancers are removed without curative intent in order to make subsequent therapies (radiation, drugs, or other adjunctive measures) more effective and, thereby, improve overall survival. Generally, the rule of thumb is to not operate if the cancer is not believed to be curable by surgery; but, large tumors may be interfering with other organs or other necessary bodily functions, or may be causing pain, but the patient’s prognosis for death is not imminent. Surgical debulking often improves the patient's situation in these cases.
Post Edited (Casey59) : 12/12/2012 9:58:13 AM (GMT-7)
I too, don't understand the "myth" part of your question either. It's not a myth, its a strategy that is used when its in the best interest of a patient's cancer situation.
david in sc
Age: 60, 56 at PC dx, PSA 16.3
3rd Biopsy: 9/8 7 of 7 Positive, 40-90%, 4+3
open RP: 11/8, Catheter in 63 days
Path Rpt: 3+4, pT2c, 42g, 20% tumor, 1 pos margin
Incont & ED: None
Surgery Failed, recurrence within 9 months
Salvage Radiation 10/9-11/9, SRT failed within 9 months, PSA 4/12 = 37.x
Spent total of 1 ½ years on 21 catheters, Ileal Conduit Surgery 9/10,
7 other PC-related surgeries
Member of Prostate Cancer & Chronic Pain HW Communities since 10/2008
“I live in the weak and the wounded” – Session Nine (Movie)
Father (69 now) diagnosed with PCs in Jan 2011:
DRE positive, PSA 7.5, biopsy Gleason 6, second expert opinion: Gleason 7 and 8.
two inconclusive bone-scintigraphies, MR scan showed 2 bone mets
Feb 2011: Started hormonal therapy (Trelstar+Casodex) in Jan 2011
Jan 2012: Added Zometa
Mar 2012: went "off" hormonal therapy after PSA reached 0.055
I guess I asked this question because the term is used a lot here by posters, yet not sure if this approach is also popular in medical community. Perhaps, under a different name, or described differently?
Father (69 now) diagnosed with PCs in Jan 2011:
DRE positive, PSA 7.5, biopsy Gleason 6, second expert opinion: Gleason 7 and 8.
two inconclusive bone-scintigraphies, MR scan showed 2 bone mets
Feb 2011: Started hormonal therapy (Trelstar+Casodex) in Jan 2011
Jan 2012: Added Zometa
Mar 2012: went "off" hormonal therapy after PSA reached 0.055
"Debulking is the surgical removal of part of a malignant tumour which cannot be completely excised, so as to enhance the effectiveness of radiation or chemotherapy. It is used only in specific malignancies, as generally partial removal of a tumor is not considered a worthwhile intervention. Ovarian carcinoma and some types of brain tumor are debulked prior to commencing radio- or chemotherapy. It may also be used in the case of slow growth tumors to shift tumor cells from phase of cell cycle to replicative pool."
http://en.wikipedia.org/wiki/Debulking
Post Edited (SpecialLady) : 12/12/2012 10:41:19 AM (GMT-7)
from the study:
Radical prostatectomy (RP) achieved excellent survival rates in high-risk PCa, even in patients with very high PSA level.
compared to...? I´m having a bit trouble understanding how the authors reached their conclusion.
If I read it correctly then it seems to bear on a recent discussion in another thread in which worriedaboutHubby's hubby's urologist was criticized for doing a RP with a pre-op PSA of 81. The debulking review seems to support the urologist's approach. Or did I miss something?
60
Slow PSA rise 2007-2012: 1.4=>8
4 biopsies 2010-2012:
1)neg (inflammation observed),
2)neg,
3)positive one of 14 cores GS6(3+3) 3-4%, 2nd opinion GS7(3+4)
4)neg.
Moderate Pre-op ED
DaVinci RRP 6/14/12. left nerve spared
Post-op path: pT3a pN0 R1 GS9(4+5) Pos margins on rt
Start 24 mo ADT (Triple w/ Lupron) 7/26/12
Start adjuvant IMRT 10/17/12 done 12/13/12
Incontinent, Trimix, VED for Rehab
>>>> (after I got really poor evaluations of possibility to cure from multiple ROs).
Just out of interest, if they didn't have reason to believe that the cancer had broke through the capsule, why did they think radiation was a bad idea?
Father (69 now) diagnosed with PCs in Jan 2011:
DRE positive, PSA 7.5, biopsy Gleason 6, second expert opinion: Gleason 7 and 8.
two inconclusive bone-scintigraphies, MR scan showed 2 bone mets
Feb 2011: Started hormonal therapy (Trelstar+Casodex) in Jan 2011
Jan 2012: Added Zometa
Mar 2012: went "off" hormonal therapy after PSA reached 0.055
Father (69 now) diagnosed with PCs in Jan 2011:
DRE positive, PSA 7.5, biopsy Gleason 6, second expert opinion: Gleason 7 and 8.
two inconclusive bone-scintigraphies, MR scan showed 2 bone mets
Feb 2011: Started hormonal therapy (Trelstar+Casodex) in Jan 2011
Jan 2012: Added Zometa
Mar 2012: went "off" hormonal therapy after PSA reached 0.055
I´m having a bit trouble understanding how the authors reached their conclusion.
That is a common problem with abstracts of "review" type studies. The "data" they summarize is about the other studies they looked at and how those studies were selected. The data on which those constituent studies made their conclusions is not generally included in the abstract of the review study.
So, they reached their conclusion the same way we are, by reading other studies. I think the study that proscapt linked was one of the ones cited in the review study.